IN BRIEF: Biotech Growth Trust outperforms benchmark in full-year

Fri, 04th Jun 2021 19:22

Biotech Growth Trust PLC - investment firm - Reports net asset value per share total return of 55% for the year to the end of March, and share price total return of 75%, both significantly outperforming the benchmark, the NASDAQ Biotechnology Index (sterling adjusted), which rose by 25% over the year. The discount of the company's share price to its NAV per share narrowed to 1.4% as at March 31 from 13% the year before. NAV per share rose to 1,446.4p from 932.4p year-on-year.

Current stock price: 1,360.00p, up 1.0% on Friday

Year-to-date change: down 14%

By Evelina Grecenko; evelinagrecenko@alliancenews.com

Biotech Gwth